{"name":"Pia Osterlund","slug":"pia-osterlund","ticker":"","exchange":"","domain":"","description":"Pia Osterlund is a biopharmaceutical company focused on developing innovative treatments in oncology. The company's lead candidate is a combination therapy involving bevacizumab plus alternating XELOX/XELIRI, currently in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiV0FVX3lxTFBnb3ZCY0IwczI0bEsyUEs3NU44ME9ubDNWR21GZU5OQldQOEQzOUNJSWlTem9ZX3lURGZMV3F6WERaTFJtUlpFVi1tUVJWcVFrNU93bHl4MA?oc=5","date":"2021-01-14","type":"pipeline","source":"ASCO Publications","summary":"Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice - ASCO Publications","headline":"Nutrition in Cancer Care: A Brief, Practical Guide With a Focus on Clinical Practice","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}